NMDA Receptor Modulators
978-3-639-90938-8
3639909380
108
2010-09-02
39.00 €
eng
https://images.our-assets.com/cover/230x230/9783639909388.jpg
https://images.our-assets.com/fullcover/230x230/9783639909388.jpg
https://images.our-assets.com/cover/2000x/9783639909388.jpg
https://images.our-assets.com/fullcover/2000x/9783639909388.jpg
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. NMDA Receptor Modulators (glutamate antagonists) are a new form of antipsychotic that are in Phase II FDA study. The first compound studied was glycine which was hypothesized by Dr. Daniel Javitt "www.esi-topics.com/schizophrenia/interviews/Dr-Daniel-Javitt.html" after observation that people with PCP induced psychosis were lacking in glutamate transmission. In giving glycine to people with PCP induced psychosis a recovery rate was noted. From there, it was hypothesized that people with psychosis from schizophrenia would benefit from increased glutamate transmission and glycine was added with strong recovery rates noted especially in the area of negative and cognitive symptoms.
https://morebooks.de/books/tr/published_by/betascript-publishing/1/products
Bilişim
https://morebooks.de/store/tr/book/nmda-receptor-modulators/isbn/978-3-639-90938-8